Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Thursday, 16th of January, 2025
Cambridge, UK & Monheim, DE -- Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs).
“GPCRs remain one of the toughest challenges in antibody discovery because it’s so difficult to generate the key to success—high-quality target material,” said Marion Cubitt, Director of Discovery at Isogenica. “Cube’s Native MPTMtechnology unlocks these targets for discovery, while Isogenica’s synthetic approach means only small quantities are needed, keeping costs low. By combining our strengths, we’re simplifying GPCR discovery and helping drug developers innovate faster.”
“Our collaboration with Isogenica combines Cube’s expertise in GPCR stabilisation with Isogenica’s synthetic VHH platform to create a robust, flexible solution for the pharmaceutical industry,” said Barbara Maertens, Founder and COO of Cube Biotech. “We’re helping innovators tackle some of the most challenging targets in medicine, driving progress in GPCR drug discovery.”
Press Inquiries: Michael Ries
Head of Sales and Marketing, Cube Biotech
Email: michael.ries@cube-biotech.com
A Strategic Collaboration with Flexibility
This collaboration combines Cube Biotech’s advanced GPCR stabilisation technology with Isogenica’s proprietary synthetic VHH libraries and CIS Display technology, creating a seamless solution for GPCR-targeted therapeutics. The two companies will work together to support Pharma and Biotech with high quality antigens and VHH therapeutics to address high-value GPCR targets like GLP-1R whilst still maintaining the flexibility of working with other providers depending on customer needs.“GPCRs remain one of the toughest challenges in antibody discovery because it’s so difficult to generate the key to success—high-quality target material,” said Marion Cubitt, Director of Discovery at Isogenica. “Cube’s Native MPTMtechnology unlocks these targets for discovery, while Isogenica’s synthetic approach means only small quantities are needed, keeping costs low. By combining our strengths, we’re simplifying GPCR discovery and helping drug developers innovate faster.”
A Seamless Solution for GPCR Discovery
GPCRs are among the most complex and valuable targets in drug discovery, underpinning advances in metabolic disorders, oncology, and neurology. This collaboration supports discovery teams with:- Stabilised GPCR Targets: Cube Biotech’s proprietary stabilisation technology delivers functional GPCRs ideal for antibody discovery workflows.
- Synthetic VHH Libraries: Isogenica’s libraries offer an animal-free alternative to traditional methods, optimised to reduce material requirements and accelerate timelines for GPCR discovery.
- Streamlined Expertise: The collaboration offers a proven, integrated approach that reduces risks and accelerates progress for pharmaceutical innovators tackling GPCRs.
Why It Matters for GLP-1R and Beyond
The vast therapeutic and market opportunity that GPCRs represent has been recently exemplified by GLP-1R—a target driving innovation in weight-loss therapies. With this strong focus, Isogenica and Cube Biotech have deepened their collaboration to support a wide range of structurally complex transmembrane proteins which are notoriously inaccessible as drug targets without specialised support. By combining stabilised GPCRs with advanced synthetic VHH discovery, they provide a platform to unlock both current and future therapeutic opportunities to help their partners find the next GLP-1R blockbuster.“Our collaboration with Isogenica combines Cube’s expertise in GPCR stabilisation with Isogenica’s synthetic VHH platform to create a robust, flexible solution for the pharmaceutical industry,” said Barbara Maertens, Founder and COO of Cube Biotech. “We’re helping innovators tackle some of the most challenging targets in medicine, driving progress in GPCR drug discovery.”
Cube is picking up the pace: Isogenica is the fourth of a series of strategic partnerships. Stay tuned!
About Isogenica
Isogenica accelerates drug discovery with synthetic VHH antibodies designed for precision and speed. Using our proprietary libraries and CIS Display technology, we empower pharmaceutical innovators to overcome the toughest challenges in therapeutic development. For more information, visit isogenica.com.About Cube Biotech
Cube Biotech specialises in membrane protein technologies and purification solutions, enabling breakthroughs in complex drug discovery workflows. Their NativeMPTM copolymer platform stabilises any membrane protein in its native lipid environment, enhancing the reliability and precision of functional assays and downstream applications. They also offer an extensive purification resin and magnetic bead portfolio.Let's Work Together
Ready to advance GPCR-targeted therapeutics? Contact us today to learn how this collaboration can streamline your drug discovery pipeline.Press Inquiries: Michael Ries
Head of Sales and Marketing, Cube Biotech
Email: michael.ries@cube-biotech.com